Safety of Alemtuzumab in Patients with Multiple Sclerosis: Interim Results of a Post-Authorization Safety Study (PASS)

被引：0
|
作者：
Montalban, X. [1 ]
Van Wijmeersch, B. [2 ]
Gobbi, C. [3 ]
Robertson, N. [4 ]
Klotz, L. [5 ]
Achiron, A. [6 ]
Lee, A. [7 ]
Eichau, S. [8 ]
Vecsei, L. [9 ]
Benzerdjeb, H. [10 ]
Rodrigues, A. [10 ,11 ]
Jurgensen, S. [11 ]
Chirieac, M.
Comi, G. [12 ,13 ]
机构：
[1] Hosp Univ Vall Hebron, Dept Neurol Neuroimmunol, Ctr dEsclerosi Multiple Catalunya Cemcat, Barcelona, Spain
[2] Univ Hasselt, Hasselt, Belgium
[3] Neuroctr Southern Switzerland, Dept Neurol, Multiple Sclerosis Ctr MSC, EOC, Lugano, Switzerland
[4] Univ Hosp Wales, Cardiff, Wales
[5] Univ Munster, Munster, Germany
[6] Chaim Sheba Med Ctr, Tel Hashomer, Israel
[7] Flinders Univ S Australia, Adelaide, SA, Australia
[8] Hosp Univ Virgen Marcarena, Seville, Spain
[9] Univ Szeged, Szeged, Hungary
[10] Sanofi, Chilly Mazarin, France
[11] Sanofi Cambridge, Cambridge, MA USA
[12] Casa Cura Policlin, Milan, Italy
[13] Univ Vita Salute San Raffaele, Milan, Italy
来源：
EUROPEAN JOURNAL OF NEUROLOGY | 2022年 / 29卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
EPR-165
引用
收藏
页码：288 / 288
页数：1
相关论文
共 50 条
  • [1] Design of a Multinational Post-Authorization Safety Study (PASS) of Crizotinib
    Ehrenstein, Vera
    Huang, Kui
    Kahlert, Johnny
    Bahmanyar, Shahram
    Karlsson, Par
    Lofling, Lukas
    Bezemer, Irene D.
    Kuiper, Josine G.
    Nunes, Anthony P.
    Enger, Cheryl
    Hoti, Fabian
    Juuti, Rosa
    Korhonen, Pasi
    Mo, Jingping P.
    Schachterle, Stephen
    Sorensen, Henrik T.
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2017, 26 : 311 - 312
  • [2] Italian multiple sclerosis register as the basis for post-authorization safety studies
    Ponzio, M.
    Trojano, M.
    Capobianco, M.
    Pugliatti, M.
    Ulivelli, M.
    Mosconi, P.
    Patti, F.
    Zaratin, P.
    Lepore, V.
    Battaglia, M. A.
    EUROPEAN JOURNAL OF PUBLIC HEALTH, 2020, 30 : V998 - V998
  • [3] POST-AUTHORIZATION SAFETY OF LENALIDOMIDE plus DEXAMETHASONE IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA: EARLY SAFETY REPORT OF TURKISH PASS STUDY
    Tuglular, A. T. Firatli
    Pehlivan, M.
    Sari, H. I.
    Ayyildiz, M. O.
    Saydam, G.
    Sonmez, M.
    Besisik, S. Kalayoglu
    Ozgur, G.
    Gurkan, E.
    Kaynar, L.
    Ali, R.
    Ozet, G.
    Demirkan, F.
    Ongoren, S.
    Ozdogu, H.
    Gunduz, E.
    Tiftik, E. N.
    Salim, O.
    Turgut, M.
    Hacihanefioglu, A.
    Ure, U. B.
    Ozdemir, E.
    Altuntas, F.
    Simsek, D.
    Ulu, N.
    Beksac, M.
    HAEMATOLOGICA, 2015, 100 : 734 - 734
  • [4] Alemtuzumab post authorization safety study (PASS) study design: Evaluating the long-term safety profile of alemtuzumab in patients with RRMS
    Montalban, X.
    Rodriguez-Antiguedad, A.
    Forner, M.
    Colilla, S.
    Margolin, D. H.
    EUROPEAN JOURNAL OF NEUROLOGY, 2017, 24 : 320 - 320
  • [5] EUROPEAN POST-AUTHORIZATION SECURITY STUDY (EU PASS) OF MULTIPLE MYELOMA IN RELAPSED/REFRACTORY: SAFETY OF PATIENTS TREATED WITH POMALIDOMIDE
    Ramirez Payer, A.
    Di Raimondo, F.
    Kyriakou, C.
    Schmidt-Hieber, M.
    Bentsen, P. T.
    Lauri, B.
    Kueenburg, E.
    Atiba-Davies, M.
    Lersch, F.
    Rosettani, B.
    Bacon, P.
    Plesner, T.
    HAEMATOLOGICA, 2017, 102 : 107 - 107
  • [6] Post-authorization safety surveillance (PASS) for rAHF-PFM: final EU and US safety and efficacy results
    Oldenburg, J.
    Luu, H.
    Spotts, G.
    Gajek, H.
    Kriukov, A.
    Stephens, D.
    Berg, R.
    Barker, K.
    Ewenstein, B.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2009, 7 : 821 - 821
  • [7] Liver safety of tolvaptan in patients with autosomal dominant polycystic kidney disease: interim data from a post-authorization safety study
    Jaeger, Thomas
    Lohrmann, Emanuel
    Ezenekwe, Adachukwu
    Enekebe, Kene
    Kumar, Retesh
    Nunna, Sasikiran
    Fernandes, Ancilla W.
    McCormick, Linda
    George, Vinu
    CLINICAL KIDNEY JOURNAL, 2024, 17 (11)
  • [8] Experience of Joint Post-Authorization Safety Studies (PASS) through an Example
    Kurzinger, Marie-Laure
    Juhaeri, Juhaeri
    Chang, Cristina
    Auclert, Laurent
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2014, 23 : 477 - 477
  • [9] Non-Interventional Post-Authorization Safety Study (PASS) on the Long-Term Safety of HYQVIA® (IGHY)
    Fielhauer, K.
    Nikolov, N.
    Hermann, C.
    Nagy, A.
    Schiff, R. I.
    JOURNAL OF CLINICAL IMMUNOLOGY, 2014, 34 : S294 - S294
  • [10] Agomelatine post-authorization safety studies program: Comprehensive results
    Jacquot, Emmanuelle
    Olivier, Valerie
    Percheron, Christele
    Mazens, Fanny
    Deltour, Nicolas
    Perez-Gutthann, Susana
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2019, 28 : 246 - 246
12345